{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:19:32Z","timestamp":1784179172485,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF2015-8088"],"award-info":[{"award-number":["KWF2015-8088"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Peritoneal metastases (PM) in colorectal cancer (CRC) are associated with therapy resistance and poor survival. Oxaliplatin monotherapy is widely applied in the intraperitoneal treatment of PM, but fails to yield clinical benefit. We aimed to identify the mechanism(s) underlying PM resistance to oxaliplatin and to develop strategies overcoming such resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Experimental design<\/jats:title>\n                <jats:p>We generated a biobank consisting of 35 primary tumour regions and 59 paired PM from 12 patients. All samples were analysed by RNA sequencing. We also generated a series of PM-derived organoid (PMDO) cultures and used these to design and test strategies to overcome resistance to oxaliplatin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PM displayed various hallmarks of aggressive CRC biology. The vast majority of PM and paired primary tumours belonged to the Consensus Molecular Subtype 4 (CMS4). PMDO cultures were resistant to oxaliplatin and expressed high levels of glutamate-cysteine ligase (GCLC) causing detoxification of oxaliplatin through glutathione synthesis. Genetic or pharmacological targeting of GCLC sensitised PMDOs to a 1-h exposure to oxaliplatin, through increased platinum-DNA adduct formation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results link oxaliplatin resistance of colorectal PM to their CMS4 status and high reducing capacity. Inhibiting the reducing capacity of PM may be an effective strategy to overcome PM resistance to oxaliplatin.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-01742-5","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T07:02:46Z","timestamp":1645513366000},"page":"1824-1833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity"],"prefix":"10.1038","volume":"126","author":[{"given":"Jamila","family":"Laoukili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Constantinides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C. E.","family":"Wassenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd G.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle A. E.","family":"Raats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne J.","family":"van Schelven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"van Wettum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Volckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon W.","family":"Nienhuijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H. J. T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 J.","family":"Wiezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helma M. U.","family":"van Grevenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inne H. M. Borel","family":"Rinkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila","family":"Boerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-4390","authenticated-orcid":false,"given":"Onno","family":"Kranenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"1742_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263\u20137.","journal-title":"J Clin Oncol"},{"key":"1742_CR2","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709\u201319.","journal-title":"Lancet Oncol"},{"key":"1742_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350\u20136.","journal-title":"Nat Med"},{"key":"1742_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/jnci\/djw303","volume":"109","author":"I Ubink","year":"2017","unstructured":"Ubink I, Elias SG, Moelans CB, Lacle MM, van Grevenstein WMU, van Diest PJ, et al. A novel diagnostic tool for selecting patients with mesenchymal-type colon cancer reveals intratumor subtype heterogeneity. J Natl Cancer Inst. 2017;109:8.","journal-title":"J Natl Cancer Inst"},{"key":"1742_CR5","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1002\/bjs.10788","volume":"105","author":"I Ubink","year":"2018","unstructured":"Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, van Grevenstein WMU, et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg. 2018;105:e204\u2013e11.","journal-title":"Br J Surg"},{"key":"1742_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamaoncol.2016.2314","volume":"2","author":"N Song","year":"2016","unstructured":"Song N, Pogue-Geile KL, Gavin PG, Yothers G, Kim SR, Johnson NL, et al. Clinical outcome from oxaliplatin treatment in stage II\/III colon cancer according to intrinsic subtypes: secondary analysis of NSABP C-07\/NRG oncology randomized clinical trial. JAMA Oncol. 2016;2:1162\u20139.","journal-title":"JAMA Oncol"},{"key":"1742_CR7","doi-asserted-by":"crossref","unstructured":"Linnekamp JF, Hooff SRV, Prasetyanti PR, Kandimalla R, Buikhuisen JY, Fessler E, et al. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differ. 2018;25:616\u201333.","DOI":"10.1038\/s41418-017-0011-5"},{"key":"1742_CR8","doi-asserted-by":"crossref","unstructured":"Trinh A, Trumpi K, de Sousa EMF, Wang X, de Jong JH, Fessler E, et al. Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry. Clin Cancer Res. 2016;23:387\u201398.","DOI":"10.1158\/1078-0432.CCR-16-0680"},{"key":"1742_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.48","volume":"6","author":"K Trumpi","year":"2017","unstructured":"Trumpi K, Ubink I, Trinh A, Djafarihamedani M, Jongen JM, Govaert KM, et al. Neoadjuvant chemotherapy affects molecular classification of colorectal tumors. Oncogenesis. 2017;6:e357.","journal-title":"Oncogenesis."},{"key":"1742_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Quenet","year":"2021","unstructured":"Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:256\u201366.","journal-title":"Lancet Oncol"},{"key":"1742_CR11","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, Hubner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368\u2013e77.","journal-title":"Lancet Oncol"},{"key":"1742_CR12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","volume":"106","author":"I Ubink","year":"2019","unstructured":"Ubink I, Bolhaqueiro ACF, Elias SG, Raats DAE, Constantinides A, Peters NA, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg. 2019;106:1404\u201314.","journal-title":"Br J Surg"},{"key":"1742_CR13","doi-asserted-by":"crossref","unstructured":"Lau HCH, Kranenburg O, Xiao H, Yu J. Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol. 2020;17:203\u201322.","DOI":"10.1038\/s41575-019-0255-2"},{"key":"1742_CR14","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","volume":"141","author":"T Sato","year":"2011","unstructured":"Sato T, Stange DE, Ferrante M, Vries RG, van Es JH, Van den BS, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium. Gastroenterology 2011;141:1762\u201372.","journal-title":"Gastroenterology"},{"key":"1742_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015;161:933\u201345.","journal-title":"Cell"},{"key":"1742_CR16","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41591-019-0584-2","volume":"25","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Wu C, O\u2019Rourke KP, Szeglin BC, Zheng Y, Sauve CG, et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat Med. 2019;25:1607\u201314.","journal-title":"Nat Med"},{"key":"1742_CR17","doi-asserted-by":"crossref","unstructured":"Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med. 2019;11:eaay2574.","DOI":"10.1126\/scitranslmed.aay2574"},{"key":"1742_CR18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920\u20136.","journal-title":"Science."},{"key":"1742_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell. 2020;26:17\u201326 e6.","journal-title":"Cell Stem Cell"},{"key":"1742_CR20","doi-asserted-by":"crossref","unstructured":"Rovers KP, Wassenaar ECE, Lurvink RJ, Creemers GM, Burger JWA, Los M, et al. Pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol. 2021;28:5311\u201326.","DOI":"10.1245\/s10434-020-09558-4"},{"key":"1742_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00216-008-2034-8","volume":"391","author":"EE Brouwers","year":"2008","unstructured":"Brouwers EE, Tibben MM, Pluim D, Rosing H, Boot H, Cats A, et al. Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. Anal Bioanal Chem. 2008;391:577\u201385.","journal-title":"Anal Bioanal Chem"},{"key":"1742_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"1742_CR23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1053\/j.gastro.2006.08.039","volume":"132","author":"LG van der Flier","year":"2007","unstructured":"van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, de PM, Anti M, et al. The intestinal Wnt\/TCF signature. Gastroenterology. 2007;132:628\u201332.","journal-title":"Gastroenterology."},{"key":"1742_CR24","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782\u201395.","journal-title":"Immunity."},{"key":"1742_CR25","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1158\/1078-0432.CCR-15-2879","volume":"22","author":"E Becht","year":"2016","unstructured":"Becht E, de Reynies A, Giraldo NA, Pilati C, Buttard B, Lacroix L, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016;22:4057\u201366.","journal-title":"Clin Cancer Res"},{"key":"1742_CR26","first-page":"1119","volume":"27","author":"J Barriuso","year":"2021","unstructured":"Barriuso J, Nagaraju RT, Belgamwar S, Chakrabarty B, Burghel GJ, Schlecht H, et al. Early adaptation of colorectal cancer cells to the peritoneal cavity is associated with activation of \u201cstemness\u201d programs and local inflammation. Cancer Res. 2021;27:1119\u201330.","journal-title":"Cancer Res"},{"key":"1742_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Bakkers C, Simkens G, Burger JWA, Nienhuijs SW, Creemers GM, et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer. 2019;19:390.","journal-title":"BMC Cancer"},{"key":"1742_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","volume":"165","author":"W Wang","year":"2016","unstructured":"Wang W, Kryczek I, Dostal L, Lin H, Tan L, Zhao L, et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell. 2016;165:1092\u2013105.","journal-title":"Cell"},{"key":"1742_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"S Rottenberg","year":"2021","unstructured":"Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21:37\u201350.","journal-title":"Nat Rev Cancer"},{"key":"1742_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2013.09.006","volume":"141","author":"GF Rushworth","year":"2014","unstructured":"Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharm Ther. 2014;141:150\u20139.","journal-title":"Pharm Ther"},{"key":"1742_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.stem.2016.04.003","volume":"18","author":"M Fujii","year":"2016","unstructured":"Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell. 2016;18:827\u201338.","journal-title":"Cell Stem Cell"},{"key":"1742_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/ng.3225","volume":"47","author":"A Calon","year":"2015","unstructured":"Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47:320\u20139.","journal-title":"Nat Genet"},{"key":"1742_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ng.3224","volume":"47","author":"C Isella","year":"2015","unstructured":"Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet. 2015;47:312\u20139.","journal-title":"Nat Genet"},{"key":"1742_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejso.2018.10.542","volume":"45","author":"W Ceelen","year":"2019","unstructured":"Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? Eur J Surg Oncol. 2019;45:400\u20132.","journal-title":"Eur J Surg Oncol"},{"key":"1742_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(20)30693-8","volume":"22","author":"SJ Klempner","year":"2021","unstructured":"Klempner SJ, Ryan DP. HIPEC for colorectal peritoneal metastases. Lancet Oncol. 2021;22:162\u20134.","journal-title":"Lancet Oncol"},{"key":"1742_CR36","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/ans.15424","volume":"89","author":"CE Koh","year":"2019","unstructured":"Koh CE, Ansari N, Morris D, Moran B. Australian, New Zealand Peritoneal Malignancy C. Beware mis-representation of PRODIGE 7: danger of throwing out the cytoreductive surgery baby with the hyperthermic intraperitoneal chemotherapy bathwater. ANZ J Surg. 2019;89:992\u20134.","journal-title":"ANZ J Surg"},{"key":"1742_CR37","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028\u201340.","journal-title":"J Clin Oncol"},{"key":"1742_CR38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl J Med. 2018;378:230\u201340.","journal-title":"N. Engl J Med"},{"key":"1742_CR39","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann surgical Oncol. 2011;18:1575\u201381.","journal-title":"Ann surgical Oncol"},{"key":"1742_CR40","doi-asserted-by":"crossref","unstructured":"Narasimhan V, Wright JA, Churchill M, Wang T, Rosati R, Lannagan TR, et al. Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy. Clin Cancer Res. 2020;26:3662\u201370.","DOI":"10.1158\/1078-0432.CCR-20-0073"},{"key":"1742_CR41","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/ars.2016.6633","volume":"26","author":"DL Kirkpatrick","year":"2017","unstructured":"Kirkpatrick DL, Powis G. Clinically evaluated cancer drugs inhibiting redox signaling. Antioxid Redox Signal. 2017;26:262\u201373.","journal-title":"Antioxid Redox Signal"},{"key":"1742_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","volume":"35","author":"H Ogiwara","year":"2019","unstructured":"Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Yoshida H, Watanabe R, et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell. 2019;35:177\u201390 e8.","journal-title":"Cancer Cell"},{"key":"1742_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 2015;27:211\u201322.","journal-title":"Cancer Cell"},{"key":"1742_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1021\/tx00039a017","volume":"7","author":"M Sharma","year":"1994","unstructured":"Sharma M, Tomasz M. Conjugation of glutathione and other thiols with bioreductively activated mitomycin C. Effect of thiols on the reductive activation rate. Chem Res Toxicol. 1994;7:390\u2013400.","journal-title":"Chem Res Toxicol"},{"key":"1742_CR45","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ccr.2012.08.013","volume":"22","author":"A Calon","year":"2012","unstructured":"Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22:571\u201384.","journal-title":"Cancer Cell"},{"key":"1742_CR46","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","volume":"31","author":"D Ciardiello","year":"2020","unstructured":"Ciardiello D, Elez E, Tabernero J, Seoane J. Clinical development of therapies targeting TGFbeta: current knowledge and future perspectives. Ann Oncol. 2020;31:1336\u201349.","journal-title":"Ann Oncol"},{"key":"1742_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/carcin\/bgr230","volume":"33","author":"J Cai","year":"2012","unstructured":"Cai J, Tang H, Xu L, Wang X, Yang C, Ruan S, et al. Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis. 2012;33:20\u20139.","journal-title":"Carcinogenesis."},{"key":"1742_CR48","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ijc.22874","volume":"121","author":"HA Kenny","year":"2007","unstructured":"Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007;121:1463\u201372.","journal-title":"Int J Cancer"},{"key":"1742_CR49","doi-asserted-by":"publisher","first-page":"e88018","DOI":"10.1371\/journal.pone.0088018","volume":"9","author":"M Kojima","year":"2014","unstructured":"Kojima M, Higuchi Y, Yokota M, Ishii G, Saito N, Aoyagi K, et al. Human subperitoneal fibroblast and cancer cell interaction creates microenvironment that enhances tumor progression and metastasis. PLoS ONE. 2014;9:e88018.","journal-title":"PLoS ONE"},{"key":"1742_CR50","first-page":"541","volume":"22","author":"Q Yao","year":"2009","unstructured":"Yao Q, Qu X, Yang Q, Wei M, Kong B. CLIC4 mediates TGF-beta1-induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer. Oncol Rep. 2009;22:541\u20138.","journal-title":"Oncol Rep."},{"key":"1742_CR51","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17:887\u2013904.","journal-title":"Nat Rev Drug Discov"},{"key":"1742_CR52","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.18632\/oncotarget.24626","volume":"9","author":"K Trumpi","year":"2018","unstructured":"Trumpi K, Frenkel N, Peters T, Korthagen NM, Jongen JMJ, Raats D, et al. Macrophages induce \u201cbudding\u201d in aggressive human colon cancer subtypes by protease-mediated disruption of tight junctions. Oncotarget. 2018;9:19490\u2013507.","journal-title":"Oncotarget."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01742-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01742-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01742-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T12:07:00Z","timestamp":1654690020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01742-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,6,1]]}},"alternative-id":["1742"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01742-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided informed consent to their tumour tissues being used for either molecular and genetic analysis, and\/or PMDO generation. PDMO samples have been collected with patient consent as part of the CRC-PIPAC study (Netherlands Trial Register NL6426\/NTR6603) and has been approved by the Medical Review Ethics Committee (NL60405.100.17). The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}